ProLynx kündigt klinische Studie der Phase IB zu seinem DNA-schädigenden Wirkstoff PLX038 (PEG~SN-38) in Kombination mit dem PARP-Inhibitor Rubraca® (Rucaparib) am National Cancer Institute an

    NEXT STORY
    The Global Nephrology Device Market is expected to grow from USD 11,952.37 Million in 2019 to USD 17,226.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%
    PREV STORY
    CORRECTION: VAXIL PROVIDES UPDATE ON PRECLINICAL EXPERIMENT
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aduro Biotech to Present at LEERINK Partners Roundtable Series

    BERKELEY, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

    author_avatar
    NASDAQ Market News

    Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine

    Study successfully achieved both primary endpoints Second positive Phase 3 demonstrating the safety and ...

    author_avatar
    NASDAQ Market News

    Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special Conference on Ovarian Cancer

    100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection ...

    author_avatar
    NASDAQ Market News